BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations
In This Article:
BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.
Oops, something went wrong
BridgeBio stock broke out Wednesday after its new heart drug, a rival to Pfizer's blockbuster Vyndaqel, smashed sales expectations.